The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review

The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review

The current standard treatment for patients with early-stage colon cancer consists of surgical resection, followed by adjuvant therapy in a select group of patients deemed at risk of cancer recurrence. The decision to administer adjuvant therapy, intended to eradicate the clinically inapparent minim...

Full description

Bibliographic Details
Main Authors: Sakti Chakrabarti, Hao Xie, Raul Urrutia, Amit Mahipal
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Cancers
Subjects:
circulating tumor DNA (ctDNA)
colon cancer
adjuvant therapy
Next-generation sequencing
minimal residual disease (MRD)
early-stage colon cancer
Online Access:https://www.mdpi.com/2072-6694/12/10/2808

Internet

https://www.mdpi.com/2072-6694/12/10/2808

Similar Items